Abstract
Ritscher-Schinzel syndrome (RSS) is a congenital malformation syndrome characterized by cerebellar, cardiac, and craniofacial malformations and phenotypes associated with liver, skeletal and kidney dysfunction. The genetic cause of RSS remains to be fully defined, and limited information is available regarding the root cause of the multiple tissue phenotypes. Here, we combine genetic and clinical analysis in patient cohorts with in-cellulo analysis and in vivo phenotypic analysis of a mouse model of RSS, to identify novel causative genes for RSS within the Commander endosomal recycling pathway. We reveal how perturbed endosomal recycling reduces tissue-specific presentation of cell surface integral membrane proteins essential for kidney, bone and brain development and how this leads to major RSS-associated clinical phenotypes including proteinuria, skeletal malformation, and neurological impairment. Our data establishes RSS as a ‘recyclinopathy’ that arises from a dysfunction in the Commander endosomal recycling pathway.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
FACS Facility, Wolfson Bioimaging Facility and Proteomics Facility funded by the Wellcome Trust (202904/Z/16/Z and 206181/Z/17/Z) and BBSRC (BB/R000484/1) at the University of Bristol. P.J.C. is supported by the Wellcome Trust (104568/Z/14/Z and 220260/Z/20/Z), the MRC (MR/L007363/1 and MR/P018807/1), the Lister Institute of Preventive Medicine, and the Royal Society Noreen Murray Research Professorship (RSRP/R1/211004). K.K is supported by JSPS KAKENHI (JP20K16897/JP23KJ1817/ JP23K14945/JP23KK0284), Japan Intractable Diseases (Nanbyo) Research Foundation, and Takeda Science Foundation. S.S. is supported by JSPS KAKENHI (JP20K21583), AMED under Grant Number (JP24ek0109646). I.H. is supported by the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED under Grant Number JP21am0101120 (Support No. 2754). K.A.F. is supported by Qatar National Research Fund (QNRF) - NPRP11S-0110-180250. K.S is supported by JSPS KAKENHI (JP20H05700).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Genetic and functional analysis using samples from study participants was approved by the institutional review boards at Nagoya City University (Approval Number: 70-00-0200), Sidra Medicine (Approval Number: IRB 1636872), and National Research Centre, Egypt (Approval Number: 20105).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
